What's Happening?
Viking Therapeutics, Inc. (VKTX) is targeting a potential launch of its lead obesity drug candidate, VK2735, in the first half of 2029. This timeline was shared by CEO Brian Lian during the company's third-quarter 2026 earnings call. The company is currently
advancing both subcutaneous (SC) and oral formulations of VK2735 through separate Phase III clinical programs. The SC version is being evaluated in two fully enrolled Phase III studies, VANQUISH-1 and VANQUISH-2, which are expected to conclude in 2027. Additionally, Viking has initiated SUNRISE, a Phase III clinical program for the once-daily oral VK2735. The company is also investing in commercial infrastructure, including establishing a core commercial leadership team and adding personnel in technical operations, manufacturing, and supply chain, in preparation for a potential market entry.
Why It's Important?
Viking Therapeutics' ambition to launch an obesity drug by 2029 places it in direct competition with established pharmaceutical giants like Eli Lilly and Novo Nordisk, who already market successful oral and injectable obesity treatments. The obesity market represents a significant commercial opportunity, and Viking's entry could intensify competition, potentially leading to more diverse treatment options and competitive pricing for consumers. The success of VK2735 would mark a major milestone for Viking, a clinical-stage company, and could significantly impact its market valuation and future growth trajectory. However, the timeline is contingent on positive clinical trial results, timely regulatory submissions, and FDA approval, with any delays potentially pushing back the launch. The company's proactive investment in commercial infrastructure underscores the high stakes and potential rewards in this rapidly expanding therapeutic area.
What's Next?
Viking Therapeutics expects top-line results from its VANQUISH studies either in late 2027 or early 2028. Assuming positive outcomes, the company could submit its regulatory filings to the FDA in the first half of 2028. A standard FDA review period of approximately 10 months would then lead to a potential decision in the first half of 2029, aligning with management's targeted launch timeframe. The company also plans to start extension studies for the VANQUISH program in the first quarter of 2027 to evaluate additional maintenance regimens. Meanwhile, competitors Eli Lilly and Novo Nordisk are also advancing next-generation therapies, indicating that the obesity market will continue to evolve with new treatments and increased competition.
Beyond the Headlines
The race to develop effective obesity treatments highlights a growing public health challenge and a significant area of pharmaceutical innovation. The increasing demand for such drugs reflects a societal shift towards addressing obesity as a chronic disease with medical interventions. Viking Therapeutics' strategy to develop both injectable and oral formulations of VK2735 demonstrates an understanding of patient preferences and market needs, aiming to offer flexible treatment options. The substantial financial investment required for late-stage clinical trials and commercial infrastructure underscores the high barriers to entry in this market. The long-term implications of this intensifying competition could include accelerated research into novel mechanisms of action, improved patient outcomes, and potentially more accessible and affordable treatments for obesity.
